Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Sep 7, 2017; 23(33): 6128-6136
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6128
Table 2 Use of first-line treatment n (%)
First-line
All newly treated patients
SSACCTTSSA + CCSSA + TTTT + CCIFSSA + IFSSA + TT + CC
n134575281423132112258
59.6%33.3%3.6%1.9%1.4%0.1%0.1%0.0%0.0%100.0%
Duration of first-line treatment (mean ± SD, d)449 ± 434.2215 ± 228.8267 ± 325.7408 ± 327.9276 ± 189.5208 ± 165.6251 ± 285.0836 ± 0426 ± 0361 ± 385.0
First-line ending status635 (47.2)609 (81.0)44 (54.3)26 (61.9)14 (45.2)1 (33.3)1 (50.0)0 (0)1 (100.0)1331 (58.9)
Stop
Switch128 (9.5)33 (4.4)14 (17.3)5 (11.9)7 (22.6)1 (33.3)1 (50.0)0 (0)0 (0)189 (8.4)
End of enrollment582 (43.3)110 (14.6)23 (28.4)11 (26.2)10 (32.3)1 (33.3)0 (0)1 (100.0)0 (0)738 (32.7)
Liver directed therapy timing
During first-line171 (12.7)87 (11.6)9 (11.1)10 (23.8)4 (12.9)1 (33.3)0 (0.0)0 (0.0)0 (0.0)282 (12.5)
After first-line36 (2.7)39 (5.2)7 (8.6)0 (0.0)2 (6.5)0 (0.0)0 (0.0)0 (0.0)0 (0.0)84 (3.7)
+/- 30 d after stopping first line therapy163560944261411011331
29 (4.6)42 (6.9)2 (4.5)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)73 (5.5)